-26.7%
ZTS vs GSK
+14.9%
-41.6%
-46.7%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | +7.5% | +5.0% | +2.5% | +5.1% |
| 7D | +15.4% | +4.9% | +10.5% | +12.9% |
| 30D | +25.8% | +9.9% | +15.9% | +20.5% |
| 3M | +18.1% | +0.2% | +17.9% | +17.6% |
| 6M | -19.7% | +2.3% | -22.1% | -21.2% |
| YTD | -27.5% | +7.1% | -34.6% | -29.7% |
| 1Y | -26.7% | +13.1% | -39.8% | -30.6% |
| All | -26.7% | +14.9% | -41.6% | -30.6% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling